Medtronic plc logo

Medtronic plc (MDT)

Market Open
3 Jul, 17:00
NYSE NYSE
$
88. 37
+0.09
+0.1%
$
110.21B Market Cap
25.14 P/E Ratio
2.76% Div Yield
656,767 Volume
5.2 Eps
$ 88.28
Previous Close
Day Range
88.06 88.7
Year Range
75.96 96.25
Want to track MDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 47 days
Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic (MDT) closed the most recent trading day at $87.17, moving +1.34% from the previous trading session.

Zacks | 2 days ago
Medtronic: Margin Inflection With Diabetes Spin - Key Drivers

Medtronic: Margin Inflection With Diabetes Spin - Key Drivers

Initiate Medtronic with Strong Buy, $161 PT, citing a structural margin inflection from Diabetes spin-off and robust innovation pipeline (120+ approvals). Street underestimates FY27 margin/EPS upside from Diabetes separation and operating leverage in Cardiac & Structural Heart—key drivers for re-rating. Valuation at 26x FY27E EPS is conservative versus peers; scenario analysis shows risk skewed to the upside, as margin catalysts execute.

Seekingalpha | 4 days ago
Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap

Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap

I reiterate my buy rating on Medtronic, driven by solid fundamentals and an attractive valuation, despite less upside versus prior estimates. Medtronic continues to deliver steady revenue growth, robust free cash flow, and a 48-year dividend growth streak, even as sector sentiment weakens. Key risks include competitive pressures, margin threats in Diabetes and CAS, and macro headwinds like tariffs, requiring prudent management execution.

Seekingalpha | 5 days ago
Medtronic Board appoints Dr. Joon Lee as a new director

Medtronic Board appoints Dr. Joon Lee as a new director

GALWAY, Ireland , June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board.

Prnewswire | 1 week ago
Why Is Medtronic (MDT) Up 6% Since Last Earnings Report?

Why Is Medtronic (MDT) Up 6% Since Last Earnings Report?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 week ago
Medtronic: Solid Recent Performance But Better Options Available

Medtronic: Solid Recent Performance But Better Options Available

Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the stock's recent gains stem from a low base, and it still trades well below its 2021 highs. Earnings growth is steady but uninspiring, with margin pressure and tariff risks highlighting operational challenges versus higher-quality competitors.

Seekingalpha | 2 weeks ago
Medtronic announces MiniMed as name for planned New Diabetes Company

Medtronic announces MiniMed as name for planned New Diabetes Company

GALWAY, Ireland , June 12, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.

Prnewswire | 3 weeks ago
Medtronic Announces Intent To Spin Diabetes Business

Medtronic Announces Intent To Spin Diabetes Business

Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.

Forbes | 3 weeks ago
I'm Buying 2 Must-Own Dividend Bargains

I'm Buying 2 Must-Own Dividend Bargains

The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, making it attractive for conservative income investors. Medtronic provides a reliable 3.5% yield, a strong balance sheet, and growth catalysts in cardiac solutions, surgical robotics, and a value-enhancing diabetes spin-off.

Seekingalpha | 1 month ago
Medtronic plc (MDT) Bernstein's 41st Strategic Decisions Conference - (Transcript)

Medtronic plc (MDT) Bernstein's 41st Strategic Decisions Conference - (Transcript)

Medtronic plc (NYSE:MDT ) Bernstein's 41st Strategic Decisions Conference Call May 29, 2025 11:00 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Thierry Pieton - Executive Vice President and Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right. Very good.

Seekingalpha | 1 month ago
We compared 5 Dividend Aristocrats, this one came out on top

We compared 5 Dividend Aristocrats, this one came out on top

A quarter of a century of increasing dividends is a hell of a way to generate some passive income. Enter Dividend Aristocrats.

Finbold | 1 month ago
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade

Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade

Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, improving operating margins and capital allocation. Recent results show robust cardiovascular growth and strong shareholder returns, with continued buybacks expected post-spin-off.

Seekingalpha | 1 month ago
Loading...
Load More